Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.33 |
| ▸ | KIF11 | P52732 | 2/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.31 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.31 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4378404 | 0.83 | TSHR (0.41) | TSHRLMNATYRTP53GRIA4 | |
| SCHEMBL4371679 | 0.77 | TSHR (0.36) | TSHRLMNATYRTP53GRIA4 | |
| SCHEMBL4380162 | 0.77 | ACHE (0.36) | MAPT | |
| SCHEMBL4367995 | 0.75 | EPHX1 (0.34) | TSHRLMNATP53EPHX1ALDH1A1 | |
| SCHEMBL4376395 | 0.75 | TSHR (0.41) | TSHRLMNATYRTP53GRIA4 | |
| SCHEMBL4372728 | 0.74 | GRIA4 (0.38) | TSHRLMNATYRTP53GRIA4 | |
| SCHEMBL4379627 | 0.74 | TDP1 (0.38) | — | |
| SCHEMBL16489774 | 0.73 | TSHR (0.39) | TSHRLMNATYRTP53GRIA4 | |
| SCHEMBL4373239 | 0.73 | TSHR (0.39) | TSHRLMNATYRTP53GRIA4 | |
| SCHEMBL16489817 | 0.73 | TSHR (0.39) | TSHRLMNATYRTP53GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1867654-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE QUINUCLIDINOL | NAGOYA IND SCIENCE RES INST (JP) | 2014-06-11 | — | — | EP | disclosed |
| EP-2623509-A1 | Method of producing an optically active amine compound by catalytic asymmetric hydrogenation using a ruthenium-diphosphine complex | Kanto Kagaku Kabushiki Kaisha (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-20130197234-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE COMPOUND | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2013-08-01 | — | — | US | disclosed |
| US-8212037-B2 | Process for production of optically active quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | KANTO KAGAKU KABUSHIKI KAISHA | 2009-08-27 | — | — | US | disclosed |
| EP-1867654-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE QUINUCLIDINOL | Nagoya Industrial Science Research Institute (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216019-A1 | Process for Production of Optically Active Quinuclidinols | NQO2, ADH7, MRPL21 | TSHR 2723/4885LMNA 3915/4885TYR 31/4885 |
| US-20130197234-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE COMPOUND | HRH3, TDO2, SRM | TSHR 1977/4885LMNA 4608/4885TYR 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.